3,347 Shares in Ascendis Pharma A/S (NASDAQ:ASND) Bought by DNB Asset Management AS

DNB Asset Management AS acquired a new position in shares of Ascendis Pharma A/S (NASDAQ:ASND) in the second quarter, according to its most recent 13F filing with the SEC. The institutional investor acquired 3,347 shares of the biotechnology company’s stock, valued at approximately $456,000.

Other institutional investors have also recently added to or reduced their stakes in the company. EverSource Wealth Advisors LLC boosted its position in Ascendis Pharma A/S by 37.6% during the 4th quarter. EverSource Wealth Advisors LLC now owns 333 shares of the biotechnology company’s stock worth $42,000 after acquiring an additional 91 shares during the period. GAMMA Investing LLC boosted its position in Ascendis Pharma A/S by 52.0% during the 1st quarter. GAMMA Investing LLC now owns 298 shares of the biotechnology company’s stock worth $45,000 after acquiring an additional 102 shares during the period. Quadrant Capital Group LLC boosted its position in Ascendis Pharma A/S by 90.4% during the 4th quarter. Quadrant Capital Group LLC now owns 318 shares of the biotechnology company’s stock worth $40,000 after acquiring an additional 151 shares during the period. PNC Financial Services Group Inc. boosted its position in Ascendis Pharma A/S by 1.0% during the 4th quarter. PNC Financial Services Group Inc. now owns 16,384 shares of the biotechnology company’s stock worth $2,064,000 after acquiring an additional 159 shares during the period. Finally, Mirae Asset Global Investments Co. Ltd. boosted its position in Ascendis Pharma A/S by 1.3% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 13,989 shares of the biotechnology company’s stock worth $1,762,000 after acquiring an additional 186 shares during the period.

Analysts Set New Price Targets

A number of research analysts have issued reports on the company. Morgan Stanley boosted their price target on Ascendis Pharma A/S from $116.00 to $140.00 and gave the stock an “equal weight” rating in a research report on Thursday, May 16th. TD Cowen upgraded Ascendis Pharma A/S from a “hold” rating to a “buy” rating and upped their price objective for the company from $156.00 to $175.00 in a report on Tuesday, June 25th. Wells Fargo & Company upped their price objective on Ascendis Pharma A/S from $260.00 to $262.00 and gave the company an “overweight” rating in a report on Friday, May 3rd. Stifel Nicolaus began coverage on Ascendis Pharma A/S in a report on Friday, May 31st. They issued a “buy” rating and a $200.00 price objective for the company. Finally, Cantor Fitzgerald restated an “overweight” rating and issued a $173.00 price objective on shares of Ascendis Pharma A/S in a report on Wednesday, May 15th. Two investment analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $179.00.

Ascendis Pharma A/S Stock Up 0.0 %

Shares of NASDAQ ASND traded up $0.04 during mid-day trading on Wednesday, hitting $125.55. 4,320 shares of the company traded hands, compared to its average volume of 361,440. Ascendis Pharma A/S has a 1 year low of $85.29 and a 1 year high of $161.00. The stock has a market capitalization of $7.31 billion, a price-to-earnings ratio of -13.06 and a beta of 0.63. The business has a 50 day moving average of $133.40 and a two-hundred day moving average of $139.19.

Ascendis Pharma A/S Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.